L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease

Anekonda, Thimmappa S., Quinn, Joseph F., Harris, Christopher, Frahler, Kate, Wadsworth, Teri L., Woltjer, Randall L.·2011·Neurobiology of Disease
DOI 10.1016/j.nbd.2010.08.020

Cited by (157)

Items 101–157 of 157

  1. Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
    Leslie C. Norins · 2021 · Journal of Alzheimer s Disease
  2. The Anti-Amyloid-β and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule
    Izumi Maezawa, Bende Zou, Jacopo Di Lucente, William Cao, Conrado Pascual, Sahani Weerasekara, Man Zhang, Xinmin Xie, Duy H. Hua, Lee‐Way Jin · 2017 · Journal of Alzheimer s Disease
  3. Azelnidipine Attenuates the Oxidative and NFκB Pathways in Amyloid-β-Stimulated Cerebral Endothelial Cells
    Tao Teng, Devin M. Ridgley, A. Tsoy, Grace Y. Sun, S. Askarova, J. C. Lee · 2018 · ACS Chemical Neuroscience
  4. Putative pathological mechanisms of late-life depression and Alzheimer’s disease
    S.M. Nageeb Hasan, Courtney Clarke, Tadhg Strand, Francis Rodriguez Bambico · 2023 · Brain Research
  5. Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data
    Zohara Sternberg, R. Podolsky, J. Yu, Mingmei Tian, D. Hojnacki, Bernhard J. Schaller · 2022 · The Journal of Prevention of Alzheimer s Disease
  6. Protective effects of nimodipine and lithium against aluminum-induced cell death and oxidative stress in PC12 cells.
    Jamileh Saberzadeh, Mehdi Omrani, Mohammad Ali Takhshid · 2016 · PubMed Central
  7. Grapevine Stilbenoids: Bioavailability and Neuroprotection
    Pierre Waffo‐Téguo, Stéphanie Krisa, Alison D. Pawlus, Tristan Richard, Jean‐Pierre Monti, Jean‐Michel Mérillon · 2013 · Springer eBooks
  8. Amyloid Peptide Channels
    Rustam Azimov, Bruce L. Kagan · 2015 · Springer series in biophysics
  9. A Drug Mystery of Heterocycles: Various Molecules for One Target or One Compound for Multiple Targets?
    I. M. Shcherbakova · 2013 · Chemistry of Heterocyclic Compounds
  10. Voltage-Gated Na+ Channels in Alzheimer’s Disease: Physiological Roles and Therapeutic Potential
    Timothy John Baumgartner, Zahra Haghighijoo, Nana Aboadwe Goode, Nolan Michael Dvorak, Parsa Arman, Fernanda Laezza · 2023 · Life
  11. Impacts of CACNB4 overexpression on dendritic spine density in both sexes and relevance to schizophrenia
    Emily M. Parker, Nathan L. Kindja, Rebecca A. DeGiosio, Ryan Salisbury, Josh M. Krivinko, Claire E. J. Cheetham, Matthew L. MacDonald, Weijia Fan, Bin Cheng, Robert A. Sweet · 2024 · Translational Psychiatry
  12. Role of Mitochondrial Calcium Dysregulation in Alzheimer’s Disease Pathogenesis
    Rasoul Ebrahimi, Sara Hatami, Anahita Hashempoor, Soroush Oraee, Shakiba Salarvandian, Ali Faramarzi, Khadijeh Esmaeilpour · 2025 · Molecular Neurobiology
  13. Suitability of Banana and Plantain Fruits in Modulating Neurodegenerative Diseases: Implicating the In Vitro and In Vivo Evidence from Neuroactive Narratives of Constituent Biomolecules
    Barnabas Oluwatomide Oyeyinka, Anthony Jide Afolayan · 2022 · Foods
  14. Effects of L-Type Voltage-Gated Calcium Channel (LTCC) Inhibition on Hippocampal Neuronal Death after Pilocarpine-Induced Seizure
    Changjun Lee, Songhee Lee, Beom Seok Kang, Min-Kyu Park, Hyun Wook Yang, Seo Young Woo, Se-Wan Park, Dong‐Yeon Kim, Hyun Ho Jung, Won-Il Yang et al. · 2024 · Antioxidants
  15. A molecular approach to treating cognition in schizophrenia by calcium channel blockade
    Katherine E. Burdick, M. Mercedes Pérez-Rodríguez, Rebecca Birnbaum, Megan R. Shanahan, Emmett M. Larsen, Cierra Nicole Harper, J Poskus, Pamela B. Sklar · 2020 · Schizophrenia Research Cognition
  16. Effects of novel tacripyrines ITH12117 and ITH12118 on rat vas deferens contractions, calcium transients and cholinesterase activity
    Janaína Drawanz Pereira, Afonso Caricati‐Neto, Regiane Miranda‐Ferreira, Soraya Soubhi Smaili, Rosely Oliveira Godinho, Cristóbal de los Rı́os, Rafael M. Leon, Mércedes Villarroya, Abdelouahid Samadi, José Marco‐Contelles et al. · 2011 · European Journal of Pharmacology
  17. Is a potential Alzheimer's therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?
    Anne Corbett, Clive G. Ballard · 2013 · Expert Opinion on Investigational Drugs
  18. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7
    Myriam Torres-Rico, Virginia García-Calvo, Adrián Gironda-Martínez, Jorge Pascual-Guerra, Antonio G. Garcı́a, Victoria Maneu · 2024 · Cell Calcium
  19. Pathological Calcium Signaling in Traumatic Brain Injury and Alzheimer’s Disease: From Acute Neuronal Injury to Chronic Neurodegeneration
    Stephan Neuschmid, Carla Schallerer, Barbara E. Ehrlich, Declan McGuone · 2025 · International Journal of Molecular Sciences
  20. Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances
    Maikel Kronbauer, Vinícia Garzella Metz, Karine Roversi, Laura Hautrive Milanesi, Domênika Rubert Rossato, Raquel Cristine Silva Barcelos, Marilise Escobar Bürger · 2019 · Behavioural Brain Research
  21. Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult
    Yancy Ferrer‐Acosta, Sergio R. Rodríguez-Massó, Dinely Pérez, Vesna A. Eterović, Pedro A. Ferchmin, Antonio Henrique B. Martins · 2022 · Toxicology in Vitro
  22. Amyloid Aβ25-35 Aggregates Say ‘NO’ to Long-Term Potentiation in the Hippocampus through Activation of Stress-Induced Phosphatase 1 and Mitochondrial Na+/Ca2+ Exchanger
    Alexander V. Maltsev, Anna B. Nikiforova, Natalia V. Bal, Pavel M. Balaban · 2022 · International Journal of Molecular Sciences
  23. The effect of the calcium channel blocker nimodipine on hippocampal BDNF/Ach levels in rats with experimental cognitive impairment
    Atilla Topçu, Sinan Saral, Aykut Öztürk, Özlem Saral, Ali Koray Kaya · 2023 · Neurological Research
  24. Probing the interactions between amyloidogenic proteins and bio-membranes
    Liang Ma, Xi Li, Robert B. Petersen, Anlin Peng, Kun Huang · 2023 · Biophysical Chemistry
  25. Calcium ion channels: challenges and successes in drug discovery
    Stefan I. McDonough · 2012 · Wiley Interdisciplinary Reviews Membrane Transport and Signalling
  26. Guardians of homeostasis: Natural products target metabolic reprogramming in Alzheimer’s disease
    Zhenkai Zhang, Haonan Xu, Fuxia Zhao, Zheyue Han, Juan Pan, Mengmeng Li, Wei Guan, Peng Jiang, Zhichao Hao, Yiqiang Zhang et al. · 2025 · Ageing Research Reviews
  27. The E3 Ubiquitin Ligase PRAJA1: A Key Regulator of Synaptic Dynamics and Memory Processes with Implications for Alzheimer’s Disease
    Chuhan Li, Yan Yan, Oliver Stork, Ruling Shen, Thomas Behnisch · 2025 · International Journal of Molecular Sciences
  28. Overview of the Molecular Modalities and Signaling Pathways Intersecting with β-Amyloid and Tau Protein in Alzheimer’s Disease
    Ahmed M. Elshazly, Melanie M. Sinanian, Diaaeldin M. Elimam, Sherin Zakaria · 2023 · Neuroglia
  29. Roles of microglial calcium channels in neurodegenerative diseases
    Shasha Wang, Jinyu Zhang, Jingdan Zhang, Ao Li, Zengqiang Yuan, Jinbo Cheng · 2024 · Human Brain
  30. L-type calcium channel antagonist isradipine age-dependently decreases plaque associated dystrophic neurites in 5XFAD mouse model
    Wickline, Jessica L., Smith, Sabrina, Shin, Riley, Odfalk, Kristian, Sanchez, Jesse, Javors, Martin, Ginsburg, Brett, Hopp, Sarah C. · 2023 · Neuropharmacology
  31. Calcium Modulating Effect of Polycyclic Cages: A Suitable Therapeutic Approach Against Excitotoxic-induced Neurodegeneration
    Ayodeji Olatunde Egunlusi, Sarel F. Malan, Vitalii A. Palchykov, Jacques Joubert · 2024 · Mini-Reviews in Medicinal Chemistry
  32. “The association of cardiometabolic diseases and related medications with cognitive performance: a cross-sectional observational study from Central Poland”
    Bartłomiej Konrad Sołtysik, Anna Cieślak-Skubel, Agnieszka Gutowska, Elisio M. Costa, Tomasz Kostka · 2025 · BMC Geriatrics
  33. Cav3 T-Type Voltage-Gated Ca2+ Channels and the Amyloidogenic Environment: Pathophysiology and Implications on Pharmacotherapy and Pharmacovigilance
    Anna Papazoglou, Muhammad Imran Arshaad, Christina Henseler, Johanna Daubner, Karl Broich, Jürgen Hescheler, Dan Ehninger, Britta Haenisch, Marco Weiergräber · 2022 · International Journal of Molecular Sciences
  34. Transport of Glucose by the Plasma Membrane Affects the Removal and Concentration of Ca2+ at Rest in Neurons – Implications of a Condition Prior to Alzheimer’s Disease?
    Vitor S. Alves, Manoel Arcísio-Miranda, Daniel Carneiro Carrettiero, Fernando A. Oliveira · 2020 · Neuroscience
  35. USP14 inhibitor IU1 alleviates amyloid-β mediated toxicity in Alzheimer's disease cell and worm models
    Ajish Ariyath, Eugene Hone, W. M. A. D. Binosha Fernando, Steve Pedrini, Ralph Nigel Martins, Prashant Bharadwaj · 2026 · Journal of Alzheimer s Disease
  36. Functional interdependence of divalent heavy metal ions, voltage-gated calcium channels and glutamatergic transmission in the central nervous system
    Anna Papazoglou, Andreas Lundt, Carola Wormuth, Christina Henseler, Karl Broich, Ralf Müller, Marco Weiergräber · 2016 · Journal of Systems and Integrative Neuroscience
  37. miR-137: A therapeutic candidate or a key molecular regulator in Alzheimer's disease?
    Muhammad Wasim, Junhao Guo, Zhendong Wang, Rabia Parveen, Riling Chen, Yajun Wang, Guoda Ma · 2025 · Journal of Alzheimer s Disease Reports
  38. Nonequilibrium molecular dynamics simulations of infrared laser-induced dissociation of a tetrameric Aβ42 β-barrel in a neuronal membrane model
    Viet Hoang Man, Junmei Wang, Philippe Derreumaux, Phuong Hoang Nguyen · 2020 · Chemistry and Physics of Lipids
  39. Nitric oxide signalling in hippocampal synaptic plasticity
    Beatrice M. Pigott · 2012 · UCL Discovery (University College London)
  40. A physics-informed graph neural network to approximate docking-based binding affinity for DYRK2 in Alzheimer’s drug repurposing
    Veysel Gider, Cafer Budak · 2026 · Scientific Reports
  41. Synthesis and Bio-Evaluation of N-Benzylpiperidine-8-Hydroxyquinoline Derivatives as Potential Cholinesterase Inhibitors, Metal Ion Chelators and Calcium Channel Blockers
    Fan Xiu, Siqi Xu, Chun Zhang, Li Wang · 2021 · Russian Journal of Bioorganic Chemistry
  42. Drug discovery in Alzheimer’s disease by regulating autophagy
    Tadanori Hamano, Yoshinori Endo · 2022 · Elsevier eBooks
  43. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
    Suneela Sunil Dhaneshwar, Mohammad Aadil Bhat, Anuradha Singh, Supriya Roy · 2024 · BENTHAM SCIENCE PUBLISHERS eBooks
  44. Diltiazem☆
    Mauro Cataldi · 2015 · Elsevier eBooks
  45. Calcium Channels as a Potential Therapeutic Target for Alzheimer’s Disease
    Poonam C. Sharma, Princi Thapak, Bhawana Chandwani, Harsha Kharkwal, Giriraj Thirupathirao Kulkarni, Rajendra Awasthi, Bhupesh Sharma · 2023 · Springer eBooks
  46. Effects of Aβ42 on the human proteome and compound library screening using cellular models of Alzheimer's disease
    Swananda Modak · 2013 · Research Explorer (The University of Manchester)
  47. GM1 mediates the formation and maintenance of cytotoxic Aβ oligomers
    Dong Yan Zhang, Jian Wang, Rebecca M. Fleeman, Madison K. Kuhn, Matthew T. Swulius, Elizabeth A. Proctor, Nikolay V. Dokholyan · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  48. CACNB4 overexpression decreases dendritic spine density in sex-specific manner
    Emily M. Parker, Nathan L. Kindja, Rebecca A. DeGiosio, Ryan B. Salisbury, Josh M. Krivinko, Claire E. J. Cheetham, Matthew L. MacDonald, Robert A. Sweet · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  49. Lipidhomöostase bei S1P-Lyase-Defizienz in Maus und Mensch
    Anna Katharina Spohner · 2022
  50. Modelling the contributions to hyperexcitability in a mouse model of Alzheimer’s disease
    Martin Mittag, Laura Mediavilla, Stefan Remy, Hermann Cuntz, Peter Jedlička · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  51. Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
    Ashish Sriram Mishra, M. Vasanthan M. Vasanthan, Bhavna Ghosh, Ponnurengam Malliappan Sivakumar · 2025 · Current Medicinal Chemistry
  52. Grapevine Stilbenoids: Bioavailability and Neuroprotection
    Pierre Waffo‐Téguo, Stéphanie Krisa, Alison D. Pawlus, Tristan Richard, Jean‐Pierre Monti, Jean‐Michel Mérillon · 2025 · Springer eBooks
  53. Molecular chaperones as therapeutic gatekeepers in Alzheimer’s disease: Intersections with Tau aggregation, amyloid burden, and neuroinflammation
    Yukti, Anushka Sharma, Sarthak Dhar, Rupal Ojha, Vijay Kumar Prajapati · 2025 · Advances in protein chemistry and structural biology
  54. Emergent therapeutic agents in the treatment of Parkinson's disease
    Doaa S. R. Khafaga, Eman K. Abdelhadi, Ziad ElDosoky Farouk, Darin W Aswa, Ahmed T. Elhendawy, Amera M. Ghazi, Radwa N. Selim, Ahmed Tharwat Al-Namrouti, Esraa A. Elgayar, Manar T El-Morsy et al. · 2026 · Elsevier eBooks
  55. BindingDB Entry 50018480: A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.
    BindingDB · 2024 · UC San Diego
  56. BindingDB Entry 50001887: Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
    BindingDB · 2020 · UC San Diego
  57. BindingDB Entry 50018520: Furazans in Medicinal Chemistry.
    BindingDB · 2024 · UC San Diego